close

Enter

Log in using OpenID

Structural Heart Devices Market To Grow Like Never Before By 2026

embed
Structural heart diseases refer to cardiac defects, which are congenital (by birth) in nature and also includes the abnormalities developed in valves and vessels of the heart caused by wear or tear due to some disease. Structural heart diseases is a
Structural Heart Devices Market Estimated to
Record Highest CAGR by 2026
Structural Heart Devices Market, by Product Type (Heart Valve (Transcatheter
Heart Valve, Mechanical Heart Valve, and Surgical Heart Valve), Annuloplasty
rings, and Occlusion Devices), by Indication (Valvular Heart Disease
(Regurgitation and Stenosis), Cardiomyopathy, Congenital Heart Defects, and
Others), by End User (Hospitals and Ambulatory Surgical Centers), and by
Geography - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Structural heart diseases refer to cardiac defects, which are congenital (by birth) in nature and also
includes the abnormalities developed in valves and vessels of the heart caused by wear or tear due to
some disease. Structural heart diseases is a non-coronary abnormality of heart, which does not affect
the blood vessels in the heart. Common structural heart condition includes atrial septal defect, patent
foramen oval, ventricular septal defect, paravalvular leak, arterial/venous fistulae, and congenital heart
disease. Click To Read More On Structural Heart Devices Market.
Structural Heart Devices Market Drivers
In 2017, Medtronic plc. received the U.S. Food and Drug Administration (FDA) approval for its new
CoreValve Evolut PRO valve for the treatment of severe aortic stenosis in symptomatic patients who
are at high or extreme risk for open heart surgery. Moreover, the company has launched CoreValve
Evolut PRO valve in the U.S. market in the same year. In 2017, Medtronic plc. received CE Mark for
its CoreValve Evolut R 34 mm valve and launched it in European market. CoreValve Evolut R 34 mm
is the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. In 2015,
Edwards Lifesciences Corporation, an U.S.-based company focused on heart valves and hemodynamic
monitoring received U.S. Food and Drug Administration (FDA) approval for its Edwards SAPIEN 3
valve, a transcatheter aortic heart valve used for the treatment of high-risk patients suffering from
severe, symptomatic aortic stenosis. Furthermore, companies operating in the area are looking to
expand product portfolio through inorganic growth. For instance, in 2015, CryoLife, Inc., an U.S.based medical device company acquired the U.S. based On-X Life Technologies Holdings, Inc., a
privately held mechanical heart valve company. CryoLife, Inc. entered in mechanical valve market with
On-X Life Technologies Holdings, Inc.’s products with this strategic acquisition.
Structural Heart Devices Market Key Players
Key players in global structural heart devices market include Abbott Laboratories, Medtronic Plc.,
Edwards Lifesciences Corporation, Boston Scientific Corporation, CryoLife Inc., LivaNova Plc., Cook
Group Incorporated, Endologix Inc., and W. L. Gore & Associates, Inc. Key players in the market are
focused on strategic merger and acquisition in order to expand its structural heart device product
portfolio.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1559
For instance, in 2017, Edwards Lifesciences Corporation, an U.S. based medical device manufacturer,
acquired Harpoon Medical, Inc. in US$ 100 cash and additional US$150 million in milestone payments
over 10 years. With this strategic acquisition Edwards Lifesciences Corporation has widen its offerings
with mitral valve repair technology, which is designed to reduce the amount of time required for mitral
valve surgery.
Structural Heart Devices Market Taxonomy
The global structural heart devices market is segmented on the basis of product type, indication, end
user, and region.
•Product Type
•Heart Valve
•Transcatheter Heart Valve
•Mechanical Heart Valve
•Surgical Heart Valve
•Annuloplasty rings
•Occlusion Devices
•Indication
•Valvular Heart Disease
•Regurgitation
•Stenosis
•Cardiomyopathy
•Congenital Heart Defects
•Others
•End User
•Hospitals
•Ambulatory Surgical Centers
Structural Heart Devices Market Regional Analysis
North America is expected to hold a dominant position in global structural heart devices market, owing
to continued research for the development of novel product and subsequent launches by major key
players present in the region. For Instance, in 2017, Edwards Lifesciences Corporation, an U.S-based
company is focusing on Launch of SAPIEN 3 Ultra and CENTERA Valves. SAPIEN 3 Ultra system is
a next-generation platform with expandable Axela sheath technology and on-balloon delivery design.
This novel product is expected to accelerate the make procedures with less chances of mistakes.
Furthermore, Europe is expected to witness significant growth in structural heart devices market, owing
to increasing prevalence of Valvular Heart Disease (VHD) in the region. According to a study
published in British Medical Journal (BMJ) in 2017, incidence of VHD was 63.9 per 100 000 personyears, with aortic stenosis (AS; 47.2%), mitral regurgitation (MR; 24.2%) and aortic regurgitation (AR;
18.0%). The study analyzed nationwide hospital data between 2003 and 2010 to reach to this
conclusion.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran300   documents Email
Document
Category
Health and Medicine
Views
3
File Size
383 KB
Tags
market
1/--pages
Report inappropriate content